



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CTX-471

Cat. No.:	HY-P99178
CAS No.:	2377152-49-1
Molecular Formula:	CT
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K_d values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer ^[1] .								
IC₅₀ & Target	Kd for CD137: 50 nM (human); 61 nM (cynomolgus macaque); 748 nM (mouse) ^[1]								
In Vitro	<p>CTX-471 (5-500 nM) has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K_d values of 50 nM, 61 nM and 748 nM, respectively^[1].</p> <p>CTX-471 binds to a unique epitope on CD137^[1].</p> <p>CTX-471 (0.1-100 nM; 1, 10 µg/mL; 3 days) increases IFN-γ production by human T cells in an FcγR-dependent (FcγR-dependent) manner in vitro^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>CTX-471 (i.p.; 150 µg) exhibits curative monotherapy activity in various syngeneic tumor models and shows a unique ability to cure mice of very large tumors. CTX-471 (i.v.; 10-80 mg/kg; on days 0, 7, 14, and 21) is well tolerated, with no signs of hepatic toxicity in high doses.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>BALB/c mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>150 µg; 10-80 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p., on days 6, 9, 12, 19 and 26(or on days 7, 10, 13, 20, and 27 or on days 0, 3, 6, and 9); i.v., on days 0, 7, 14, and 21</td> </tr> <tr> <td>Result:</td> <td>Required T and NK cells, as well as FcγR engagement to achieve its efficacy. Do not induce hepatic inflammation.</td> </tr> </table>	Animal Model:	BALB/c mice ^[1]	Dosage:	150 µg; 10-80 mg/kg	Administration:	i.p., on days 6, 9, 12, 19 and 26(or on days 7, 10, 13, 20, and 27 or on days 0, 3, 6, and 9); i.v., on days 0, 7, 14, and 21	Result:	Required T and NK cells, as well as FcγR engagement to achieve its efficacy. Do not induce hepatic inflammation.
Animal Model:	BALB/c mice ^[1]								
Dosage:	150 µg; 10-80 mg/kg								
Administration:	i.p., on days 6, 9, 12, 19 and 26(or on days 7, 10, 13, 20, and 27 or on days 0, 3, 6, and 9); i.v., on days 0, 7, 14, and 21								
Result:	Required T and NK cells, as well as FcγR engagement to achieve its efficacy. Do not induce hepatic inflammation.								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA